Multibranch Feature Difference Learning Network for Cross-Spectral Image Patch Matching

Chuang Yu(Shenyang Institute of Automation), Zhuhua Hu(Hainan University), Lin Qi(Linyi University), Xin Xia(Shenyang Institute of Automation), Yunpeng Liu(Shenyang Institute of Automation), Chenxi Li(Shenyang Institute of Automation), Tianci Liu(Shenyang Institute of Automation)
IEEE Transactions on Geoscience and Remote Sensing
January 1, 2022
10.1109/tgrs.2022.3176358
Cited by 12

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
|The Lancet Oncology|2015|412